Why Do We Need ADAMTS13?

Overview

Journal Nihon Kessen Shiketsu Gakkai shi

Date 2011 Jun 29

PMID 21709769

Authors

Han-Mou Tsai

Affiliations

Soon will be listed here.

References

Tsai H, Nagel R, Hatcher V, Sussman I . Endothelial cell-derived high molecular weight von Willebrand factor is converted into the plasma multimer pattern by granulocyte proteases. Biochem Biophys Res Commun. 1989; 158(3):980-5. DOI: 10.1016/0006-291x(89)92818-0. View

Savasan S, Lee S, Ginsburg D, Tsai H . ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood. 2003; 101(11):4449-51. DOI: 10.1182/blood-2002-12-3796. View

Goodship T, Liszewski M, Kemp E, Richards A, Atkinson J . Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends Mol Med. 2004; 10(5):226-31. DOI: 10.1016/j.molmed.2004.03.006. View

Tarr P, Gordon C, Chandler W . Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005; 365(9464):1073-86. DOI: 10.1016/S0140-6736(05)71144-2. View

Kaul D, Nagel R, Chen D, Tsai H . Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood. 1993; 81(9):2429-38. View

Tsai H, Li A, Rock G . Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab. 2001; 47(7-8):387-92. View

Veyradier A, Obert B, Houllier A, Meyer D, Girma J . Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood. 2001; 98(6):1765-72. DOI: 10.1182/blood.v98.6.1765. View

Tsai H . Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost. 2003; 29(5):479-88. DOI: 10.1055/s-2003-44556. View

Studt J, Kremer Hovinga J, Antoine G, Hermann M, Rieger M, Scheiflinger F . Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood. 2004; 105(2):542-4. DOI: 10.1182/blood-2004-06-2096. View

10.

Cal S, Obaya A, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C . Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene. 2002; 283(1-2):49-62. DOI: 10.1016/s0378-1119(01)00861-7. View

11.

Bianchi V, Robles R, Alberio L, Furlan M, Lammle B . Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002; 100(2):710-3. DOI: 10.1182/blood-2002-02-0344. View

12.

Zheng X, Nishio K, Majerus E, Sadler J . Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem. 2003; 278(32):30136-41. PMC: 11033693. DOI: 10.1074/jbc.M305331200. View

13.

Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot G . Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004; 83(4):233-244. DOI: 10.1097/01.md.0000133622.03370.07. View

14.

Tsai H . Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J Mol Med (Berl). 2002; 80(10):639-47. DOI: 10.1007/s00109-002-0369-8. View

15.

Pham P, Danovitch G, Wilkinson A, Gritsch H, Pham P, Eric T . Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation. 2002; 74(8):1077-80. DOI: 10.1097/00007890-200210270-00003. View

16.

Mannucci P, Canciani M, Forza I, Lussana F, Lattuada A, Rossi E . Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001; 98(9):2730-5. DOI: 10.1182/blood.v98.9.2730. View

17.

Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V . Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002; 71(2):105-8. DOI: 10.1002/ajh.10204. View

18.

Furlan M, Robles R, Solenthaler M, Lammle B . Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood. 1998; 91(8):2839-46. View

19.

Reiter R, Knobl P, Varadi K, Turecek P . Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood. 2002; 101(3):946-8. DOI: 10.1182/blood-2002-03-0814. View

20.

Tsai H . Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996; 87(10):4235-44. View